Its future clinical value lies in the early detection of PTVD patients through these SNPs; and because HMGCR and NPC1L1 are the target sites of statins and ezetimibe in patients with CHD, we can further investigate whether these SNPs can provide clues to the precise treatment of drugs in patients with PTVD. Here, NPC1L1 is linked to coronary artery disorder.